Wednesday, July 8, 2026

pharma · Plaque Psoriasis · Moderate-to-Severe Plaque Psoriasis · ORKA

Oruka Therapeutics

Oruka Therapeutics clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Waltham, USA HQ
78 Employees
Public company Type
ORKA · NYSE Ticker
Company details
Status
Public
HQ
Waltham, USA
Employees
78
Programs
6
Drugs
3
Patents
0
Intelligence · Clinical Programs

Oruka Therapeutics projects

6 ClinicalTrials.gov programs sponsored by Oruka Therapeutics.

Oruka Therapeutics has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. ORKA-001

    Oruka Therapeutics

    Plaque Psoriasis

    phase 2 small molecule active

    2 trials
  2. ORKA-001 Induction Dose

    Oruka Therapeutics

    Plaque Psoriasis

    phase 2 small molecule active

    1 trial
  3. ORKA-001, Placebo for ORKA-001

    Oruka Therapeutics

    Moderate-to-Severe Plaque Psoriasis

    phase 2 small molecule active

    1 trial
  4. ORKA-002

    Oruka Therapeutics

    Plaque Psoriasis

    phase 2 small molecule active

    1 trial
  5. ORKA-001

    Oruka Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial
  6. ORKA-002

    Oruka Therapeutics

    Healthy Volunteers

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Oruka Therapeutics have?

6 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.